secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001619856-24-000063
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou Q2 net loss $37.7M; extends cash runway to H2 2026 after 12% workforce cut
--------------------------------------------------------------------------------

- Net loss $37.7M in Q2 2024 vs $29.5M in Q2 2023; cash & equivalents $311.8M at June 30, down from $372.4M.
- Discontinued preclinical CAR-NK platform; reduced workforce ~12% to extend cash runway into H2 2026.
- CB-010 ANTLER enrolling ~20 2L LBCL and ~10 prior CD19 relapsed patients; initial data expected H1 2025.
- CB-011 CaMMouflage dose-escalation data for r/r multiple myeloma planned by year-end 2024.
- Appointed autoimmune expert Terri Laufer, MD to SAB; CB-010 GALLOP lupus trial initiation expected by year-end 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000063/0001619856-24-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985624000063/crbu-20240806.htm
  HTML page:      https://secwatch.observer/filing/0001619856-24-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer